AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06377748 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined facilitated tucking and ShotBlocker
Description: Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will place the ShotBlocker on the procedure site and apply pressure to the skin for 20 seconds. At the end of the time, the nurse will grasp the tissue with the ShotBlocker and inject the vaccine through the central opening. After the injection is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin. The newborn will continue to take facilitated tucking position until 1 minute after the ShotBlocker is removed.
Study NCT06684626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: Treatment typically involves fluoroquinolones alone, such as levofloxacin.
Study NCT06684626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: Treatment typically involves fluoroquinolones alone, such as levofloxacin.
Study NCT04874428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg Oral Tablet
Description: Administration of one single dose of rivaroxaban (10 mg) in tablet form.
Study NCT04874428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg Oral Tablet
Description: Administration of one single dose of apixaban (2.5 mg) in tablet form.
Study NCT06691334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection
Description: Active comparator: PRP 3 cycles of platelet-rich plasma injection treatment in 4 weeks intervals. Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under the urethra. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).
Study NCT06691334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hifu procedure and PRP injection
Description: Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under urethra.And intravaginal Hifu in4 weeks intervals. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).
Study NCT06691217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANAKINUMAB (ILARIS®)
Description: Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
Study NCT06691217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
Study NCT06693414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored health promotion education
Description: 14 weeks tailored education
Study NCT06693414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing education
Description: 14 weeks nursing education
Study NCT06693414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine nursing education
Description: 14 weeks nursing education
Study NCT06693921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI/guided block graft
Description: The allo-dentin tooth graft will be prepared by placing a dentin block from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template.
Study NCT06693921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI/guided shell graft
Description: The allo-dentin shell graft will be prepared by placing a dentin shell from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template
Study NCT06693544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut protein
Description: Commercially available plant-based protein powders
Study NCT06692400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal tube suctioning
Description: Endotracheal tube suctioning occurs as part of normal care for intubated patients. This procedure will serve as the painful procedure to assess CPOT and biomarkers of hypoxia and oxidative stress.
Study NCT06693778 — intervention group
Intervention type: OTHER
Intervention: electronic Clinical Decision Support tool for risk stratification of pediatric patients with mTBI
Description: eCDS tool for risk stratification of pediatric mTBI patients
Study NCT06692582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrolysed saline rinse
Description: EOS ph = 7, 200 ppm free available Chlorine
Study NCT06692582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrolysed saline rinse
Description: EOS ph = 7, 200 ppm free available Chlorine
Study NCT06549777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SE-group
Description: Psychoeducation and information about treatment possibilities + SE-treatment
Study NCT06549777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Psychoeducation and information about treatment possibilities + Phone
Study NCT06692582 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electrolysed saline rinse
Description: EOS ph = 7, 200 ppm free available Chlorine
Study NCT06708156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate eye drops 0.01%
Description: Drug: 0.01% atropine sulfate eye drops Dosage form and strength: 0.01% (0.4 mL: 0.04 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
Study NCT06708156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate eye drops 0.02%
Description: Drug: 0.02% atropine sulfate eye drops Dosage form and strength: 0.02% (0.4 mL: 0.08 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
Study NCT06708156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo eye drops
Description: Drug: placebo eye drops Dosage form and strength: 0.4 mL eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
Study NCT06706336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radon mitigation system
Description: standard radon mitigation system used to reduce radon in homes
Study NCT06706336 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: inactive radon mitigation system
Study NCT06747260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intranasal breast milk
Description: We administer own-mother's fresh, expressed within 4 hours, breast milk intranasally to neonates with hypoxic-ischemic encephalopathy receiving therapeutic hypothermia, starting from the first day of life and continuing for 28 days. Dose: 2 times daily, 0.4 ml in each nostril (15 minutes apart)
Study NCT06747312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab+SOC
Description: 10mg/kg once a month for 18 months
Study NCT06747312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
Study NCT06747312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
Study NCT06746168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locoregional anesthesia
Description: The FTB + iPACK group will receive 12 ml 0,5% ropivacaine for the FTB and 20 ml of ropivacaine 0.5% for the iPACK block under US guidance after spinal anesthesia
Study NCT06746168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic Ropivacaine
Description: The control group (LIA) will receive 120 ml 0.25% ropivacaine for surgical LIA placement.
Study NCT06088914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Description: Anodal tDCS will be delivered for 5 consecutive days. Participants will receive 2 mA of stimulation for 20 minutes with the anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
Study NCT06746545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib+S-1
Description: Fruquintinib: 5 mg, oral, once daily，2w/1w；Q3W S-1：40-60 mg (dosed according to body surface area), oral，2w/1w；Q3W
Study NCT06747741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PNF stretching(Contract relax with agonist contraction)
Description: 1.Passively dorsiflex the patient's foot then ask to perform active planterflexion against resistance and hold for 7-10 sec then ask patient to perform dorsiflexion to the maximum available range.
Study NCT06747741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Static Stretching:(Seated Calf Stretch With a Resistance Band)~1. Sit on the floor with your legs extended.~2. Loop a resistance band around one foot, holding both sides of it with your hands.~3. Gently pull your toes toward your shin until you feel the stretch in your calf.Repeat on the other side.~Isometric Calf Raise:~1. Stand with feet shoulder-width apart and arms at sides.~2. Engage your abs for stability and roll up onto the balls of your feet, lifting both heels off the floor.~3. Hold for 5 seconds, then return to the starting position. Frequency : 5 reps with 5-7Sec hold,3 days per week for 4 weeks (alternatively)
Study NCT06475599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule + TQB2450 injection
Description: Anlotinib hydrochloride capsule is a multi-target tyrosine kinase inhibitor, which targets VEGFR (VEGFR-1, VEGFR-2 and VEGFR-3), PDGFR, FGFR and c-Kit, etc. It can inhibit tumor progression by inhibiting angiogenesis and tumor growth at the same time.~TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1) that prevents the binding of PD-L1 to the PD-1 and B7.1 receptors on the T-cell surface, allowing T-cell reactivation and thus enhancing the immune response.
Study NCT06746662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnobreastfeeding training and consultancy
Description: Hypno-breastfeeding Education Group~A counseling program based on hypno-breastfeeding philosophy, where 4-week education content will be presented to pregnant adolescents in their 28-30th week of pregnancy and applications will be made, will be implemented with 4 sessions and 6 follow-up
Study NCT05360329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial geniculate artery embolization
Description: The procedure will be performed in local anaesthesia. An antegrade percutaneous transfemoral approach with super-selective catheterisation of geniculate neovesselswill be performed and subsequently the target will be pruned with microspherical embolic material.
Study NCT06475599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs (including Paclitaxel, Albumin, Doxorubicin and Doxorubicin hydrochloride) for treatment.
Study NCT06411860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a subcutaneous (SC) injection of placebo.
Study NCT04937946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl will be administered as an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour. The infusion will be administered through a peripheral line. Fentanyl infusion will be initiated within 24 hours after the start of mechanical ventilation and will be continued until the end of mechanical ventilation, and not longer than 5 days .
Study NCT06088914 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Sham tDCS will be delivered for 5 consecutive days. Participants will receive sham stimulation for 20 minutes with the current intensity ramping down after 30 seconds of stimulation. The anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
Study NCT04691544 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: Delivered by enema
Study NCT06411860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Participants will receive a SC injection of olpasiran at dose level 1 or 2.
Study NCT06411860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.
Study NCT04691544 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: Delivered by enema
Study NCT06027996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorbable Antibacterial Matrix
Description: Soft tissue support coated with antibiotics
Study NCT05766891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery
Study NCT05766891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room
Study NCT05766891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 3
Description: Participants will receive standard general anesthesia and medications during surgery to control your pain.
Study NCT05208814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H single dose
Description: 10 mg TPN171H taken once
Study NCT06570538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 300 mL of 0.25% ropivacaine, the mode was intermittent pumping, and the parameters were set as follows: 30 mL of the first dose, 5 mL/h of the background dose, and 10 mL of the pumping every 6h for the first 24 hours after the operation.
Study NCT06570538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil 2.0 μg/kg, 0.9% saline diluted to 100 mL, background dose of 2 ml/h, no loading dose, activated after extubation and continued until 48 hours postoperatively.
Study NCT06569927 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Utilization of a perioperative position management protocol for congenital microtia patients based on the ADDIE model.
Description: Key elements included formation of a multidisciplinary team，perioperative postural management, preoperative sleeping posture adaptability training, neck movement training, standardization of head position angles and head suspension time during surgery, use of protective headrests, attention to transfer and handover procedures, and specially designed pillows.
Study NCT06570889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol D3
Description: Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
Study NCT06570889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
Study NCT06122597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ConcenTrace
Description: The product contains concentrated seawater from Utah's inland sea.
Study NCT06571097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoﬂoxacin
Description: 0.5g/day for 2 weeks
Study NCT06062485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib+Toripalimab+AG
Description: This is a single-arm, prospective, exploratory clinical study of unresectable or relapsing metastatic ampullary tumors who were not systematically treated with surufatinib in combination with PD-1 antibody and AG regimen.Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.The AG regimen does not exceed 8 cycles, and maintenance therapy with surufatinib combined with toripalimab can be continued if the patient has not progressed after 8 cycles. The treatment period was 21 days; Tumor treatment and survival status were recorded until disease progression (RECIST 1.1) or death (during patient treatment).~Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；AG（Albumin-bound paclitaxel: 125mg/m2，IV，d1，d8，Q3W）Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W）
Study NCT05353179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperizumab injection
Description: Meperizumab injection is a humanized monoclonal antibody of IgG1 injection
Study NCT05353179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NUCALA®
Description: NUCALA® is a humanized monoclonal antibody of IgG1 injection
Study NCT05004077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMIODARONE
Description: Assess the effectiveness of different dosing strategies of amiodarone.
Study NCT05961735 — intervention group
Intervention type: OTHER
Intervention: PECS II Block
Description: The Pecs II block is applied to the patients after induction of anesthesia .
Study NCT05961735 — intervention group
Intervention type: OTHER
Intervention: Combined Serratus Anterior Plane Block
Description: Combined Serratus Anterior Plane Block is applied to the patients after induction of anesthesia .
Study NCT04973319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment.
Study NCT04973319 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Description: Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
Study NCT04628741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Coaching Model
Description: This is a behavioral intervention which includes metacognitive strategy training and personalized strategy and external aid use training.
Study NCT04628741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Apprenticeship Approach
Description: This is a behavioral intervention which includes explicit education about traumatic brain injury, its symptoms, and individuals who may provide assistance post-injury, metacognitive strategy training and personalized strategy and external aid use training.
Study NCT05002881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moringa oleifera (E-HS-01)
Description: One capsule to be taken stat
Study NCT05002881 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moringa oleifera (E-HS-01)
Description: One capsule to be taken stat
Study NCT05002881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One capsule to be taken stat
Study NCT05002881 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule to be taken stat
Study NCT04841486 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: evaluation of women's stress
Study NCT04962100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of capacitation-associated tyrosine phosphorylation in human sperm by flow cytometry
Description: After the assessment of the macroscopic and microscopic characteristics of the sample, we will wash the sample and process it using three layers of density gradients.~In the case of samples for diagnostic analysis, the remaining volume will be incubated in at 37ºC, and 0.1-0.2 ml aliquots will be taken from the end of the processing at t0 (just before introducing the sample in the incubator), at t1 (after one hour of incubation) and at t3 (after 3 hours of incubation). Additionally, a sample will be taken after washing, prior to processing the sample with the density gradients. In the case of samples processed for insemination, an additional aliquot will be taken at the exact moment in which the insemination is carried out and the elapsed incubation time will be noted.~The evaluation of the capacitation will be carried out by analyzing the state of phosphorylation of tyrosines by flow cytometry.